Latest Immunosuppressants Stories
European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May
- The long-term safety profile was consistent with pivotal trials of Cimzia® ATLANTA, May 5, 2014 /PRNewswire/ -- UCB announced today results from the PRECiSE 3 7-year open label extension
NATICK, Mass., May 1, 2014 /PRNewswire/ -- Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has launched the Promus PREMIER(TM) Everolimus-Eluting
Expert Opinion Indicates That Humira and Cimzia Have the Best Clinical Profiles of Key Marketed Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014
The adhesion molecule CD146 plays a vital role in inflammation and offers a promising therapeutic target for treating inflammatory bowel disease (IBD) as well as preventing colitis-associated colorectal cancer, say scientists.
- Study published online in Liver Transplantation - HORSHOLM, Denmark, April 28, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study
Rheumatologists Cite Improved Health-Related Quality of Life, Improved Effect in Disease Activity among Unmet Needs, According to Findings from Decision Resources Group BURLINGTON, Mass., April
New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma
ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research
New webinar will focus on scientific and process improvements that advance Rheumatoid Arthritis (RA) drug development.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.